Medical Device News Magazine

Philips Abdominal Aortic Aneruysm (AAA) Model Provides Physicians a More Patient Friendly Solution Compared to the Current Standard of Care for Managing AAA Patients

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

January 27, 2021

Philips Abdominal Aortic Aneurysm (AAA) Model is based on 3D ultrasound, Philips AAA Model delivers clinicians accurate diagnostic information without exposing patients to high doses of radiation and nephrotoxic contrast agents.

An abdominal aortic aneurysm (AAA) is an aneurysm that forms in the lower part of the aorta. Typically, AAAs are identified incidentally during abdominal imaging exams but, in some cases, remain undetected until rupture. A ruptured AAA has an 80% mortality rate [1], emphasizing the importance of routine surveillance. Philips AAA Model integrates innovative software and leading Philips 3D ultrasound technologies into a single solution to help increase diagnostic confidence and an improved patient experience. The software automatically segments and quantifies the size of the aneurysm sac for surveillance of known native (untreated), and post-EVAR (treated) AAAs.

The current standard of care for AAAs includes 2D ultrasound and computed tomography angiography (CTA). Each of these modalities has its drawbacks, including inter-operator variability with 2D ultrasound and patient exposure to high levels of radiation and nephrotoxic contrast agents with CTA.

A recent clinical study showed that 3D ultrasound examination for native AAA surveillance has excellent inter-operator reproducibility, superior to that of 2D ultrasound, supporting the broader use of 3D ultrasound in standard AAA surveillance programs [2]. 3D ultrasound has been shown to estimate the diameter and volume of an AAA with acceptable reproducibility and an improved agreement (over 2D ultrasound) with CT [3]. Furthermore, 3D ultrasound has also been proven to correlate significantly better to 3D CT than 2D ultrasound for assessing the maximum diameter of the residual sac post-EVAR, with clinically acceptable reproducibility [4].

“Regular surveillance of abdominal aortic aneurysm patients is essential, but today’s standard of care has downsides,” said Bich Le, Senior Vice President, General Manager Ultrasound at Philips. “Philips Abdominal Aortic Aneurysm (AAA) Model seamlessly integrates leading Philips technologies including Philips Premium Ultrasound System (EPIQ Elite), Philips Array Transducer (X6-1 xMATRIX) and innovative software into a single solution, to help improve the experience and outcomes for clinicians and patients alike.”

Note: Philips will debut the AAA Model at the LINC (Leipzig Interventional Course) Summit, Europe’s premiere interventional course for vascular specialists, taking place virtually, Jan. 25-29, 2021.

The Philips Abdominal Aortic Aneurysm (AAA) Model is CE marked for sale in Europe and is FDA cleared for sale in the U.S.

[1] Age-specific incidence, risk factors, and outcome of acute abdominal aortic aneurysms in a defined population. Howard DP, Banerjee A, Fairhead JF, et al. Br J Surg. 2015;102(8):907–915. doi:10.1002/bjs.9838
[2] Clinical validation of three-dimensional ultrasound for abdominal aortic aneurysm. Ghulam, Qasam M. et al., Journal of Vascular Surgery, Volume 71, Issue 1
[3] Three-dimensional ultrasound evaluation of small asymptomatic abdominal aortic aneurysms. Bredahl, K. et al. European Journal of Vascular and Endovascular Surgery, Volume 49, Issue 3, 289 – 296
[4] Three-dimensional ultrasound improves the accuracy of diameter measurement of the residual sac in EVAR patients. K. Bredahl, M. Taudorf, A. Long, L. Lönn, L. Rouet, R. Ardon, H. Sillesen, J.P. Eiberg. European Journal of Vascular and Endovascular Surgery, Volume 46, Issue 5, 2013


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”